Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q4 FY22 Earnings Presentation
26 slides from Valiant Organics's earnings presentation, May 26, 2022
Slide 1: Valiant Organics Limited – Investor Presentation Cover Letter
•••• Valiant Organics Limited Date: May 26,2022 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, "Exchange Plaza", Plot No. C/1, Mumbai- 400 001. G Block Bandra-Kurla Complex, Sandra (E), Mum
Slide 2: Earnings Presentation | Q4-FY22/FY22
Earnings Presentation | Q4 -FY22/FY22
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 5: Chemistries And Product Basket
Chemistries And Product Basket Chlorination Hydrogenation 29% Key Products: Industries Served: Key Products: Industries Served: • Para ChloroPhenol (PCP) • Agro Chemicals • Ortho Anisidine • Dyes • Ortho ChloroPhenol (OCP) • Cosmetics • Para Anisidine • Pigments • 2,4 Di Chlorophenol (2,4 DCP) • Vet
Slide 6: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 27,000 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 7: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 8: Capex Projects
Capex Projects Installed Capacity Approx. Capex Product Project Status Remarks (MT per month) (INR Mn) Commissioned Para Nitro Aniline (PNA) & Completing phase-wise • Expansion from 550 TPM to 750 TPM at Vapi plant Ortho Chloro Para Nitro 550 ~ 70 • Full capacity addition in progress Aniline (OCPNA)
Slide 9: Q4-FY22/FY22 Highlights
Q4-FY22/ FY22 HIGHLIGHTS Valiant Organics Limited | May 2022 8
Slide 10: Quarterly and Annual Financial Highlights
QUARTERLY AND ANNUAL FINANCIAL HIGHLIGHTS Q4-FY22 Consolidated Financial Highlights FY22 Consolidated Financial Highlights INR 3,476 Mn INR 11,533 Mn Operational Revenue Operational Revenue INR 570 Mn INR 2,049 Mn Operating EBITDA Operating EBITDA 16.40% 17.77% Operating EBITDA Margin Operating EBIT
Slide 11: Q4-FY22/FY22 Operational Highlights
Q4-FY22/ FY22 Operational Highlights • Strong Revenue growth in Q4FY22 & Full Year FY22 on a YoY and QoQ basis owing to higher prices as well as volume addition on account of PAP ramp up • Raw Material prices and market volatility continued to remain under pressure due to the geopolitical situations
Slide 12: Standalone Revenues - Key Chemistries
Standalone Revenues - Key Chemistries Chlorination (INR Mn) Hydrogenation (INR Mn) Ammonolysis (INR Mn) Others (INR Mn) 1,048 824 1,200 900 300 900 784 250 QUARTERLY 1,000 800 250 800 700 700 599 800 184 479 600 200 600 500 440 600 500 150 400 400 400 300 100 300 200 200 200 50 100 100 0 0 0 0 Q4-FY
Slide 13: Volumes – Key Chemistries
Volumes – Key Chemistries Chlorination (MT) Hydrogenation (MT) Ammonolysis (MT) Other (MT) 5,000 3,500 3,000 4,900 4,500 QUARTERLY 3,450 4,400 4,800 4,745 3,400 2,500 3,350 4,300 2,000 4,700 3,300 4,200 4,100 4,024 4,062 4,600 4,499 3,250 1,500 4,500 3,200 3,137 3,134 567 4,000 1,000 3,150 3,900 4,4
Slide 14: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance Particulars (INR Mn) Q4-FY22 Q4-FY21 Y-o-Y Q3-FY22 Q-o-Q Revenue from Operations 3,476 2,340 48.5% 2,884 20.5% Total Expenses 2,906 1,757 65.4% 2,382 22.0% EBITDA 570 583 (2.2)% 502 13.5% EBITDA Margins (%) 16.40% 24.91% (851) Bps 17.41% (101) Bps Other I
Slide 15: Annual Consolidated Financial Performance
Annual Consolidated Financial Performance Particulars (INR Mn) FY22 FY21* Y-o-Y Revenue from Operations 11,533 7,548 52.8% Total Expenses 9,484 5,496 72.6% EBITDA 2,049 2,052 (0.1)% EBITDA Margins (%) 17.77% 27.19% (942) Bps Other Income 74 59 25.4% Depreciation 296 212 39.6% Finance Cost 65 50 30.0
Slide 16: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance Particulars (INR Mn) Q4-FY22 Q4-FY21 Y-o-Y Q3-FY22 Q-o-Q Revenue from Operations 2,906 1702 70.7% 2,608 11.4% Total Expenses 2,462 1,337 84.1% 2,162 13.9% EBITDA 444 365 21.6% 446 (0.4)% EBITDA Margins (%) 15.28% 21.45% (617) Bps 17.10% (182) Bps Other Inco
Slide 17: Annual Standalone Financial Performance
Annual Standalone Financial Performance Particulars (INR Mn) FY22 FY21* Y-o-Y Revenue from Operations 9,484 5,742 65.2% Total Expenses 7,834 4,170 87.9% EBITDA 1,650 1,572 5.0% EBITDA Margins (%) 17.40% 27.37% (997) Bps Other Income 56 169 (66.9)% Depreciation 273 186 46.8% Finance Cost 64 35 82.9%
Slide 18: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW Valiant Organics Limited | May 2022 17
Slide 19: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY19 FY20 FY21* FY22* Operational Income 6,923 6,749 7,548 11,533 Total Expenses 5,125 4,946 5,496 9,484 EBITDA 1,798 1,803 2,052 2,049 EBITDA Margins (%) 25.97% 26.71% 27.19% 17.77% Other Income 87 63 59 74 Depreciation 136 158 212 296 F
Slide 20: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (INR Mn) FY20 FY21* FY22* Particulars (INR Mn) FY20 FY21* FY22* EQUITY 4,007 5,086 6,489 Non-Current Assets 4,451 5,731 6,652 a) Equity Share Capital 121 272 272 a) Property, Plant and Equipment 2,729 4,967 5,303 b) Other Equity 3,736 4,747 5,856 b) Capital Wor
Slide 21: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY19 FY20 FY21* FY22* Revenue from Operations 6,060 5,836 5,742 9,484 Total Expenses 4,283 4,103 4,170 7,834 EBITDA 1,777 1,733 1,572 1,650 EBITDA Margins (%) 29.32% 29.69% 27.37% 17.40% Other Income 64 52 169 56 Depreciation 118 130 186 27
Slide 22: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY20 FY21* FY22* Particulars (INR Mn) FY20 FY21* FY22* EQUITY 3,875 5,023 6,031 Non-Current Assets 4,381 5,798 6,787 a) Equity Share Capital 121 272 272 a) Property, Plant and Equipment 2,525 4,771 5,085 b) Other Equity 3,736 4,747 5,755 b) Capital Work
Slide 23: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 14,000 2,300 80.00% 1,500 80.00% 2,052 2,049 11,533 70.00% 70.00% 2,000 12,000 1,798 1,803 10,000 60.00% 60.00% 1,700 7,548 50.00% 50.00% 8,000 6,923 6,749 1,400 40.00%
Slide 24: Capital Market Information
Capital Market Information Share Price up to 31st March, 2022 40% 30% 20% 10% 0% -10% -20% -30% -40% Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 Jan-22 Feb-22 Mar-22 Valiant Sensex Price Data (As on 31st March, 2022) INR Shareholding pattern (As on 31st March, 2022) Face Value 10.
Slide 25: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 26: Thank You
THANK YOU Valiant Organics Limited | April 2022 25